| Hemopurifier (an investigational new device |
|
A clinical stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. It captures enveloped viral pathogens and exosomes in circulating blood based on size and glycosylation. In cancer, the Hemopurifier is designed to eliminate the presence of circulating tumor (CT)-derived exosomes that facilitate immune suppression, seed the spread of metastasis, and prevent the benefit of leading cancer therapies.
Aethlon Medical, Inc. has received breakthrough device designation (BDD) for the Hemopurifier for viral and oncology indications.
Aethlon is also investigating the use of the Hemopurifier in the organ transplant setting, initially focusing on potentially removing harmful viruses and exosomes from recovered kidneys. Aethlon is currently preparing for conducting a clinical trial in Australia in patients with solid tumors, including head and neck cancer and gastrointestinal cancers. Also, it is exploring oncology trials in India. |
